Grail on Thursday announced that its CEO, Bob Ragusa, will retire and is handing the reins to its current president Josh Ofman.
The cancer screening company said the move was the culmination of long-term succession …
The process by which institutional review boards oversee clinical trials needs reforms that are “big and different” so that the US can keep pace with
Plus, news about Bayer’s Kerendia, Eli Lilly’s Ebglyss and Alto Neuroscience: 📈 CytomX’s colorectal cancer data: The biotech tested multiple doses of its antibody-drug conjugate
A maternal care startup offering virtual and in-person care just raised $12 million in new funding after dropping commercial insurers to focus on Medicaid, Endpoints
AstraZeneca’s cancer immunotherapy Imfinzi has been approved in the EU for use before and after surgery for early-stage gastric cancer.
CirCode Biomed, a Chinese startup working on an experimental class of genetic medicines known as circular RNA, has received the FDA’s blessing to begin a
Grail on Thursday announced that its CEO, Bob Ragusa, will retire and is handing the reins to its current president Josh Ofman.
The cancer screening company said the move was the culmination of long-term succession …